

Business Overview

SELIC and its subsidiaries have engaged in manufacturer, distributor (both domestic and export) including research and development as following businesses:

- Industrial adhesive
- Stickers or Self-adhesive labels
- Consumer Healthcare Product

Financial Statement

	9M24	9M23	2023	2022
--	------	------	------	------

Income Statement (MB)

Revenues	1,591.01	1,394.11	1,905.45	1,624.70
Expenses	1,380.59	1,261.52	1,703.34	1,543.38
Net Profit (Loss)	94.14	47.07	80.15	40.25

Balance Sheet (MB)

Assets	3,319.69	2,987.24	3,044.86	2,781.94
Liabilities	1,674.33	1,683.61	1,693.34	1,547.08
Shareholders' Equity	1,139.21	997.04	1,032.02	959.47

Cash Flow (MB)

Operating	196.21	118.80	172.89	128.32
Investing	-64.13	-90.66	-137.87	-615.47
Financing	110.62	-84.20	-86.57	566.40

Financial Ratio


EPS (Baht)	0.15	0.08	0.13	0.08
GP Margin (%)	29.59	26.80	27.20	22.00
NP Margin (%)	8.84	5.59	6.52	2.44
D/E Ratio (x)	1.02	1.29	1.25	1.25
ROE (%)	11.91	5.34	8.05	4.95
ROA (%)	8.99	5.15	6.93	3.32

Business Plan

Business Direction and Action Plan in 2024

- Selic focus on revenue and profit growth from all business group where our policies and strategies do cover dimensions of Environment, Social, and Governance (ESG).
- Selic continuously give priority on developing and distributing Bio-Based products that are environmentally friendly into the market as they are sustainable growth engines. In addition, we manage sustainable supply chain through supplier evaluation and supplier audit in the dimensions of Environment, Social, and Governance (ESG).
- Selic respect and treat employees with fairness as they are key resources in growing business. We provide safety workplace, career path, and better well-being.
- Selic search for investment opportunities such as JV, M&A to drive inorganic growth which there will be assessments for the highest benefit to the company and shareholders. The target business could be in the same value chain of our 3 business groups.

Sustainable Development Plan



Business Highlight

- Incubation Center Project at the Thailand Science Park, through a project with the Thailand Board of Investment.
- Invested in Meticuly Company Ltd., which manufactures and services strong and high-precision bone implants designed for individual patients.
- Invested in Devakam Apothecary Hall Co., Ltd, a manufacturer and distributor of relieving-muscle-pain products under the brand name "Nammam Muay" and established DVK Healthcare Co., Ltd. to invest in the production and distribution of healthcare products under brand Neoplast™ and Neobun™.

Performance and Analysis

Business Performance Summary

<https://www.set.or.th/en/market/news-and-alert/newsdetails?id=92351400&symbol=SELIC>

Key Milestones

- 2024:** Established new subsidiary named Selic Healthcare Co., Ltd.
- 2023:** Able to grow in line with the growth strategies through healthcare business by launching a variety of products into the market under brand "Neoplast" and "Neoban".
- 2022:** investment in Devakam Apothecary Hall Co., Ltd ("Devakam") regarding the acquisition of the ordinary shares equivalent to 50% of the total shares of Devakam after capital increase. Devakam has expertise in medical and healthcare which benefit to the investment project in manufacturing and marketing the healthcare and medical supplies under trademark/brand of Neoplast™, Neobun™.
- 2021:** Changed the shareholding and management structure of PMC Label Materials Limited (PMCT) Thailand, by moving PMC Label Materials Pte Ltd, Singapore, under the shareholding and management of PMCT.
- 2020:** Opened a distribution center in Australia under the name, Selic Australia Pty Ltd., where SELIC has 100% shareholding of the company's listed capital, and in Malaysia under the name, PMC Label Materials Sdn Bhd. (PMCM), where SELIC holds indirect shares through a PMCL subsidiary, in order to support the market expansion of SELIC and its subsidiary companies.
- 2019:** Acquired and received controlling authority of PMC Label Materials Limited (PMCT) Thailand and PMC Label Materials Pte Ltd, Singapore.

Risk Management Policy

The company is aware of risk management in order to prevent and reduce risks that may occur and affect the achievement of the vision, mission and strategy of the company. The company has established the risk management policy applying the COSO-ERM so that the directors, executives, and employee able to manage risk to an acceptable level (Risk Appetite) for determining organizational strategy and allocate resources appropriately.

Recent Awards and Recognitions


- CAC Certificate of Member (Renew#2) from Thai CAC
- List of ESG Emerging 2024 from Thaiptat Institute for the fourth consecutively year
- List of Prime Minister's Export Award 2023 (Best Thai Brand)
- List of Sustainability Disclosure Recognition 2023 from Thaiptat Institute
- SET Awards 2022: Commended Sustainability Awards from the Stock Exchange of Thailand
- CAC Change Agent Award 2022 from Thai CAC

Revenue Structure



Stock Information

mai / INDUS



as of 30/09/24	SELIC	INDUS	mai
P/E (X)	14.34	14.92	38.03
P/BV (X)	1.78	1.16	1.79
Dividend yield (%)	1.04	2.85	2.10
	30/09/24	28/12/23	30/12/22
Market Cap (MB)	1,930.68	1,380.80	1,691.07
Price (B/Share)	3.16	2.26	2.86
P/E (X)	14.34	26.51	36.30
P/BV (X)	1.78	1.38	1.77

CG Report:



Company Rating: SET ESG Ratings A

Major Shareholders

as of 01/10/2024



- นาย ณรงค์ สุวัฒนพิมพ์ (23.72%)
- MR. EK SUWATTANAPHIM (17.41%)
- นาย วิฑูรย์ รุ่งกุลสกิจ (15.10%)
- บริษัท SAHA PATHANA INTER-HOLDING PUBLIC COMPANY LIMITED (8.33%)
- นาย บพิธ ภัทรารังทอง (3.82%)
- Others (31.62%)

Company Information and Contact

- <http://seliccorp.com/>
- investorRelation@seliccorp.com
- 0-2807-3347-9
- 270 Liaphklongphasicharoengfantai Road, Nongkhaem Bangkok 10160
- Other Trading Info. : https://www.settrade.com/C04_01_stock_quote_p1.jsp?txtSymbol=SELIC

Remarks: This document is prepared by the listed company and aimed to disseminate the listed company's information to investors for only investment decision support. The listed company does not give investment advice or recommendation regarding the listed company's securities. Before making investment decisions, investors should study additional information and seek advice from relevant professionals. In no event shall the listed company be responsible for any loss or damage arising from the use of the information contained herein. The listed company reserves the right to amend the content specified in this document without prior notice. Unless otherwise permitted by the listed company, copy, modification, or dissemination of this document or the content contained herein is prohibited. In case there is any questions regarding the listed company's information, the investors may seek for additional information from the report or information which the listed company has disclosed through the Office of the Securities and Exchange Commission's and/or the Stock Exchange of Thailand's channel.